CEV regimen

chemotherapy regimen consisting of above cpds; used for treatment of small-cell lung cancer; do not confuse with CEV protocol which consists of cyclophosphamide, epirubicin & vincristine

Also Known As:

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Therapy Context: Research Results

Related Diseases

1.	Urinary Bladder Neoplasms (Bladder Cancer) 04/01/1996 - "A total of 9 patients with muscle-invasive bladder cancer (T3 or T4N0M0) were treated with a modified intra-arterial M-VEC (IA-M-VEC) regimen beginning in October 1992 to evaluate its therapeutic efficacy, and in 3 evaluable patients who subsequently underwent radical cystectomy, the possibility of bladder preservation was assessed. "
2.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/01/1995 - "We compared the efficacy and toxicity of the CEV regimen (carboplatin at 300 mg/m2 on day 1, etoposide at 100 mg/body on days 1 to 3, and vincristine at 1 mg/m2 on days 1 and 8) with the PVP regimen (cisplatin at 80 mg/m2 on day 1 and etoposide at 100 mg/body on days 1 to 3) in patients with untreated small cell lung cancer (SCLC). "
3.	Vomiting 01/01/1990 - "The CEV regimen was not significantly more myelotoxic than EV but was associated with more severe nausea, vomiting and alopecia. "
4.	Thrombocytopenia (Thrombopenia) 08/01/1984 - "Dose limiting toxicity of the VEC regimen was leukopenia which occurred in most patients and thrombocytopenia was less frequent. "
5.	Nausea 01/01/1990 - "The CEV regimen was not significantly more myelotoxic than EV but was associated with more severe nausea, vomiting and alopecia. "

Related Drugs and Biologics

1.	Carboplatin (JM8)
2.	Vincristine (Oncovin)
3.	Etoposide (VP 16)
4.	Cisplatin (Platino)

Related Therapies and Procedures

1.	Cystectomy